Replies to post #393797 on Anavex Life Sciences Corp (AVXL)

[MayoMobile]

I think I just needed a day or two to really digest the presentation and be sure I was doing it accurately.

I standby all written analysis on: https://www.sotcanalytics.com/special-edition-ctad-2022

I had minor errors on the 'data' slide from the post-CTAD video. For example I note that ADCS-ADL improved +3.5 points from baseline. But this isn't really the full story - patients had a vastly greater chance of improving +3.5 points (which is clinically meaningful) over baseline, over placebo group.

So really, my written explanation is a more clear and accurate representation of what was reported.

Going forward, I am compiling a good deal of evidence which supports the reason for Anavex's trial design, and topline readout methodology - specifically, I believe they were being mindful of requirements and expectations for EMA approval. Will make a post on that sometime soon.

[ohsaycanyousee82]

Regardless of his statement announcing his presence, he’s not there. The study of his “being” with a sample size n=1 is not sufficiently powered to make his claim.

However, if self identified as non-white and/or non- binary, he may be awarded Fast Track recognition of his presence in which case he may be able to answer your question. Otherwise, his existence is statistically insignificant and irrelevant. Fttzy will vouch for this if you need a voucher.